Biomedical subjects
A Maini
Publications and source records attributed to A Maini.
[Urinary excretion of MHPG in endogenous depression. Clinico-therapeutic index].
Explore the source record for details and available documents.
Comparative pathology of benign prostatic hyperplasia and prostate cancer.
Basic studies on the pathogenesis of prostate disease including hypertrophy and cancer have been difficult due to the lack of suitable animal models. Much effort has been directed to the development of appropriate animal models, and yet many obstacles still remain. Rodents do not develop spontaneous hypertrophy of the prostate, in fact the prostate atrophies with advancing age. Guinea pigs appear to be a good model to study the effect of hormones on the prostate gland. Microinvasive prostatic adenocarcinoma occurs spontaneously in various species of rodents, and can be induced by radiation, hormones and chemical carcinogens. The man and dog appear to be the only mammals which suffer naturally from the pathological processes of the prostate gland associated with aging. We review the currently available models for the study of benign, and malignant prostate disease and assess the strengths and weaknesses each for preclinical investigations.
Gastric emptying in patients with non ulcer dyspepsia (dysmotility type).
Non ulcer dyspepsia is a clinical entity characterized by chronic recurrent upper gastrointestinal symptoms in the absence of identifiable organic or systemic cause. Many such patients may have delayed gastric emptying which can easily be documented using radionuclide food markers. We evaluated gastric emptying patterns in 20 patients having non ulcer dyspepsia and 30 healthy controls. Gastric emptying was studied using indigenously prepared radiolabelled vegetarian solid food marker, the integrity of which had already been established and reported by us. Nine of the 20 (45%) non ulcer dyspepsia patients showed delayed gastric emptying. All these patients were administered cisapride and on reevaluation showed improvement in their upper gastrointestinal symptoms.
New developments in the use of cytokines for cancer therapy.
Cytokines, the pleiotropic immune regulatory proteins, are involved in the regulation of cell growth, differentiation and functional activation. Novel cytokines have been enumerated in rapid succession and entered the clinical arena. IL-2 is well recognized for its antitumor effects and is accepted therapy for numerous malignancies. IL-l and IL-11 are important as thrombopoetic factors while IL-6 has been introduced in clinical trials as a platelet growth factor and as an antitumor agent. IL-4 has shown growth inhibitory effects against many solid tumor cell lines in vitro, but its direct effect on human tumors in vivo remains to be explored. IL-7 may be an important addition to the current strategies of adoptive immunotherapy. IL-12 plays a fundamental role in activating antitumor cellular immunity. When given with tumor associated antigens, IL-12 has proven effective against many forms of metastatic solid tumors. Immunotoxins appear to be promising, though the antigenicity of the molecule and antibody development aspects remain to be resolved. The current review will focus on the clinical use of novel cytokines for the treatment of cancer.